Information:
Fel:
ID
36652
Beskrivning
Icotinib Versus Vinorelbine/Platinum as Adjuvant Therapy in Stage II-IIIA Non-small Cell Lung Cancer With EGFR-mutation; ODM derived from: https://clinicaltrials.gov/show/NCT02448797
Länk
https://clinicaltrials.gov/show/NCT02448797
Nyckelord
Versioner (1)
- 2019-05-28 2019-05-28 -
Rättsinnehavare
See clinicaltrials.gov
Uppladdad den
28 maj 2019
DOI
För en begäran logga in.
Licens
Creative Commons BY 4.0
Modellkommentarer :
Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.
Itemgroup-kommentar för :
Item-kommentar för :
Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.
Eligibility Non-small Cell Lung Cancer NCT02448797
Eligibility Non-small Cell Lung Cancer NCT02448797
- StudyEvent: Eligibility
Similar models
Eligibility Non-small Cell Lung Cancer NCT02448797
- StudyEvent: Eligibility
Name
Typ
Description | Question | Decode (Coded Value)
Datatyp
Alias
Adenocarcinoma of lung | Status post Excision
Item
pathologically confirmed lung adenocarcinoma after surgical resection
boolean
C0152013 (UMLS CUI [1])
C0231290 (UMLS CUI [2,1])
C0728940 (UMLS CUI [2,2])
C0231290 (UMLS CUI [2,1])
C0728940 (UMLS CUI [2,2])
Disease TNM clinical staging
Item
stage ii-iiia disease according to 7th edition of tnm staging
boolean
C0012634 (UMLS CUI [1,1])
C3258246 (UMLS CUI [1,2])
C3258246 (UMLS CUI [1,2])
EGFR Exon 19 Mutation Positive | EGFR Exon 21 Mutation Positive
Item
positive egfr gene mutation (19/21)
boolean
C4289656 (UMLS CUI [1,1])
C1514241 (UMLS CUI [1,2])
C4289654 (UMLS CUI [2,1])
C1514241 (UMLS CUI [2,2])
C1514241 (UMLS CUI [1,2])
C4289654 (UMLS CUI [2,1])
C1514241 (UMLS CUI [2,2])
ECOG performance status
Item
ecog 0-1
boolean
C1520224 (UMLS CUI [1])
Life Expectancy
Item
at least 1-year life expectancy
boolean
C0023671 (UMLS CUI [1])
Organ function
Item
adequate organ function
boolean
C0678852 (UMLS CUI [1])
Cancer treatment Systemic | Chemotherapy | Targeted Therapy | Monoclonal Antibodies | Small Molecule Tyrosine kinase inhibitor
Item
previous systemic anti-tumor therapy, including chemotherapy or targeted therapy(including but not limited to monoclonal antibodies, small molecule tyrosine kinase inhibitor, etc
boolean
C0920425 (UMLS CUI [1,1])
C0205373 (UMLS CUI [1,2])
C0392920 (UMLS CUI [2])
C2985566 (UMLS CUI [3])
C0003250 (UMLS CUI [4])
C1328819 (UMLS CUI [5,1])
C1268567 (UMLS CUI [5,2])
C0205373 (UMLS CUI [1,2])
C0392920 (UMLS CUI [2])
C2985566 (UMLS CUI [3])
C0003250 (UMLS CUI [4])
C1328819 (UMLS CUI [5,1])
C1268567 (UMLS CUI [5,2])
Cancer Other | Exception Basal cell carcinoma | Exception Carcinoma in situ of uterine cervix
Item
other co-existing malignancies or malignancies diagnosed within the last 5 years with the exception of basal cell carcinoma or cervical cancer in situ
boolean
C1707251 (UMLS CUI [1])
C1705847 (UMLS CUI [2,1])
C0007117 (UMLS CUI [2,2])
C1705847 (UMLS CUI [3,1])
C0851140 (UMLS CUI [3,2])
C1705847 (UMLS CUI [2,1])
C0007117 (UMLS CUI [2,2])
C1705847 (UMLS CUI [3,1])
C0851140 (UMLS CUI [3,2])
LUNG RIGHT PNEUMONECTOMY
Item
pneumonectomy of right lung
boolean
C0746225 (UMLS CUI [1])
Toxicity chronic Due to Cancer treatment | Resolution Lacking
Item
any unresolved chronic toxicity from previous anticancer therapy
boolean
C0600688 (UMLS CUI [1,1])
C0205191 (UMLS CUI [1,2])
C0678226 (UMLS CUI [1,3])
C0920425 (UMLS CUI [1,4])
C1514893 (UMLS CUI [2,1])
C0332268 (UMLS CUI [2,2])
C0205191 (UMLS CUI [1,2])
C0678226 (UMLS CUI [1,3])
C0920425 (UMLS CUI [1,4])
C1514893 (UMLS CUI [2,1])
C0332268 (UMLS CUI [2,2])
Hypersensitivity Investigational New Drugs
Item
allergic to study drug
boolean
C0020517 (UMLS CUI [1,1])
C0013230 (UMLS CUI [1,2])
C0013230 (UMLS CUI [1,2])